Niklas Mattsson-Carlgren

Oct 12, 2024 | alzres.biomedcentral.com | Anna Svenningsson |Diana I. Bocancea |Erik Stomrud |Frederik Barkhof |Niklas Mattsson-Carlgren |Sebastian Palmqvist | +3 more

Dec 4, 2023 | jamanetwork.com | Niklas Mattsson-Carlgren |Amsterdam Neuroscience |Brain imaging |Erik Stomrud

Key PointsQuestion  Can plasma biomarkers serve as prescreening tools to identify individuals suitable for treatment with antiamyloid immunotherapies in Alzheimer disease, ie, amyloid β (Aβ)–positive individuals who do not yet have too much tau in the brain? Findings  This cohort study demonstrated the efficacy of using plasma p-tau217 values to both rule out Aβ-negative individuals and identify Aβ-positive individuals who are likely to have high tau burden.

Jul 3, 2023 | n.neurology.org | Claudia Cicognola |Niklas Mattsson-Carlgren |Danielle van Westen |Henrik Zetterberg

AbstractBackground and Objectives Injured pericytes in the neurovascular unit release platelet-derived growth factor β (PDGFRβ) into the CSF. However, it is not clear how pericyte injury contributes to Alzheimer disease (AD)–related changes and blood-brain barrier (BBB) damage. We aimed to test whether CSF PDGFRβ was associated with different AD-associated and age-associated pathologic changes leading to dementia.

May 3, 2023 | n.neurology.org | Claudia Cicognola |Niklas Mattsson-Carlgren |Danielle van Westen |Henrik Zetterberg

REQUIREMENTSYou must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information. Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.